Kremer W B
Ann Intern Med. 1975 May;82(5):684-8. doi: 10.7326/0003-4819-82-5-684.
Cytarabine is an effective agent in the treatment of acute leukemia. Since its approval by The Food and Drug Administration in 1969, the clinical effectiveness of this drug has increased as knowledge of its pharmacologic and biologic properties has been translated into clinical trials. A complete remission rate of greater than 50% can be achieved when cytarabine is used in combination with other agents in the treatment of adult acute myeloblastic leukemia. Remissions occur only after the development of significant bone-marrow hypoplasia, and the care of patients through this period of pancytopenia requires elaborate supportive techniques and facilities. The role of cytarabine in the treatment of acute lymphoblastic leukemia and lymphoma is still under clinical investigation and appears promising. Because the clinical effectiveness of cytarabine in the treatment of nonmalignant diseases has not been proved, its use in these disorders must be considered investigational and weighed against the serious bone-marrow suppression and potential long-term hazards of this drug.
阿糖胞苷是治疗急性白血病的一种有效药物。自1969年被美国食品药品监督管理局批准以来，随着对其药理和生物学特性的了解转化为临床试验，这种药物的临床疗效有所提高。当阿糖胞苷与其他药物联合用于治疗成人急性髓细胞白血病时，完全缓解率可超过50%。缓解仅在出现明显的骨髓发育不全后才会发生，在全血细胞减少的这段时间里对患者的护理需要精心的支持技术和设施。阿糖胞苷在治疗急性淋巴细胞白血病和淋巴瘤中的作用仍在临床研究中，且前景看好。由于阿糖胞苷在治疗非恶性疾病方面的临床疗效尚未得到证实，其在这些疾病中的使用必须被视为试验性的，并权衡该药物严重的骨髓抑制作用和潜在的长期危害。
